Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma.
The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...